tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Scorpion Stings D065008 1 associated lipids
Drug-Related Side Effects and Adverse Reactions D064420 3 associated lipids
Retrognathia D063173 1 associated lipids
End Stage Liver Disease D058625 1 associated lipids
Candidiasis, Invasive D058365 2 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Thrombotic Microangiopathies D057049 1 associated lipids
Central Serous Chorioretinopathy D056833 1 associated lipids
Leukoencephalopathies D056784 3 associated lipids
Netherton Syndrome D056770 1 associated lipids
Latent Tuberculosis D055985 1 associated lipids
Invasive Pulmonary Aspergillosis D055744 1 associated lipids
Keratosis, Actinic D055623 3 associated lipids
Multiple Pulmonary Nodules D055613 2 associated lipids
Pancreatitis, Graft D055589 1 associated lipids
Failed Back Surgery Syndrome D055111 3 associated lipids
Primary Graft Dysfunction D055031 1 associated lipids
Idiopathic Interstitial Pneumonias D054988 1 associated lipids
Dendritic Cell Sarcoma, Interdigitating D054739 1 associated lipids
Precursor Cell Lymphoblastic Leukemia-Lymphoma D054198 10 associated lipids
Posterior Leukoencephalopathy Syndrome D054038 1 associated lipids
Dysuria D053159 1 associated lipids
Nocturia D053158 1 associated lipids
Delayed Graft Function D051799 2 associated lipids
Renal Insufficiency D051437 8 associated lipids
Lymphohistiocytosis, Hemophagocytic D051359 1 associated lipids
Granulomatosis, Orofacial D051261 2 associated lipids
Atherosclerosis D050197 85 associated lipids
Dyslipidemias D050171 7 associated lipids
Diabetes Complications D048909 4 associated lipids
Hepatic Insufficiency D048550 1 associated lipids
Colitis, Collagenous D046729 1 associated lipids
Protoporphyria, Erythropoietic D046351 1 associated lipids
Coproporphyria, Hereditary D046349 1 associated lipids
Ileus D045823 3 associated lipids
Intestinal Volvulus D045822 1 associated lipids
Cholecystolithiasis D041761 2 associated lipids
Mastocytosis, Cutaneous D034701 1 associated lipids
Hypoalbuminemia D034141 1 associated lipids
Hyperuricemia D033461 4 associated lipids
Papillomavirus Infections D030361 4 associated lipids
Denys-Drash Syndrome D030321 1 associated lipids
Pulmonary Disease, Chronic Obstructive D029424 16 associated lipids
Polyomavirus Infections D027601 1 associated lipids
Coronary Stenosis D023921 6 associated lipids
Lacerations D022125 1 associated lipids
Brachial Plexus Neuritis D020968 2 associated lipids
Neuroaspergillosis D020953 2 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Central Nervous System Viral Diseases D020805 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Gaynor JJ and Ciancio G The Importance of Using Serially Measured Tacrolimus Clearance Values, Especially During the Early Posttransplantation Period. 2018 Transplantation pmid:29271869
Miyauchi T et al. Effect of donor-specific splenocytes via portal vein and FK506 in rat small bowel transplantation. 1998 Transplantation pmid:9448139
Rosen HR et al. Significance of early aminotransferase elevation after liver transplantation. 1998 Transplantation pmid:9448146
Koprak S et al. Depletion of the mature CD4+8- thymocyte subset by FK506 analogs correlates with their immunosuppressive and calcineurin inhibitory activities. 1996 Transplantation pmid:8623162
Calmus Y et al. Assessing renal function with daclizumab induction and delayed tacrolimus introduction in liver transplant recipients. 2010 Transplantation pmid:20495510
Egli A et al. Inhibition of polyomavirus BK-specific T-Cell responses by immunosuppressive drugs. 2009 Transplantation pmid:19935369
Boyer O et al. Improvement of renal function in pediatric heart transplant recipients treated with low-dose calcineurin inhibitor and mycophenolate mofetil. 2005 Transplantation pmid:15912111
Selzner N et al. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. 2009 Transplantation pmid:19935376
Numakura K et al. Clinical and genetic risk factors for posttransplant diabetes mellitus in adult renal transplant recipients treated with tacrolimus. 2005 Transplantation pmid:16340785
Khanna A et al. Donor bone marrow potentiates the effect of tacrolimus on nonvascularized heart allograft survival: association with microchimerism and growth of donor dendritic cell progenitors from recipient bone marrow. 1998 Transplantation pmid:9500620
Shihab FS et al. Donor preconditioning with a calcineurin inhibitor improves outcome in rat syngeneic kidney transplantation. 2009 Transplantation pmid:19202436
Gayowski T et al. Orthotopic liver transplantation in high-risk patients: risk factors associated with mortality and infectious morbidity. 1998 Transplantation pmid:9500623
Johnson MC et al. QT prolongation and Torsades de Pointes after administration of FK506. 1992 Transplantation pmid:1373538
Kim YI et al. Stimulation of liver regeneration by pretreatment with azathioprine as well as cyclosporine and FK506. 1992 Transplantation pmid:1373539
de Sandes-Freitas TV et al. Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus. 2015 Transplantation pmid:25929604
Ciancio G et al. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients. 2002 Transplantation pmid:11965039
Khanna A et al. Tacrolimus induces increased expression of transforming growth factor-beta1 in mammalian lymphoid as well as nonlymphoid cells. 1999 Transplantation pmid:10071036
Kessler M et al. A renal allograft recipient with late recurrence of focal and segmental glomerulosclerosis after switching from cyclosporine to tacrolimus. 1999 Transplantation pmid:10071045
Mor E et al. Late-onset acute rejection in orthotopic liver transplantation--associated risk factors and outcome. 1992 Transplantation pmid:1279849
Hirano Y et al. The effects of FK506 and cyclosporine on the exocrine function of the rat pancreas. 1992 Transplantation pmid:1279850
van Rijen MM et al. CD154 is expressed during treatment with calcineurin inhibitors after organ transplantation. 2002 Transplantation pmid:12042657
Horner BM et al. Recipient damage after musculocutaneous transplant rejection. 2008 Transplantation pmid:18946349
di Francesco F et al. One year follow-up of steroid-free immunosuppression plus everolimus in isolated pancreas transplantation. 2008 Transplantation pmid:18946356
Bäckman L et al. FK506 trough levels in whole blood and plasma in liver transplant recipients. Correlation with clinical events and side effects. 1994 Transplantation pmid:7509516
Higgins RM et al. Acute rejection after renal transplantation is reduced by approximately 50% by prior therapeutic blood transfusions, even in tacrolimus-treated patients. 2004 Transplantation pmid:14966430
Aulagnon F et al. Diarrhea after kidney transplantation: a new look at a frequent symptom. 2014 Transplantation pmid:25073040
Mahé E et al. Drug-induced hypersensitivity syndrome associated with primary Epstein-Barr virus and human herpesvirus 6 infections in a child intestinal transplant recipient. 2004 Transplantation pmid:14966435
Boillot O et al. Reversal of early acute rejection with increased doses of tacrolimus in liver transplantation: a pilot study. 1998 Transplantation pmid:9825815
Tanaka M et al. Effect of anticomplement agent K76 COOH on hamster-to-rat and guinea pig-to-rat heart xenotransplantation. 1996 Transplantation pmid:8830837
Opelz G Comparison of FK506 and cyclosporine. 1996 Transplantation pmid:8830844
Yoshimura N et al. Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. I. Inhibition of expression of alloantigen-activated suppressor cells, as well as induction of alloreactivity. 1989 Transplantation pmid:2465592
Abadja F et al. Impact of mycophenolic acid and tacrolimus on Th17-related immune response. 2011 Transplantation pmid:21818055
Piao SG et al. Combined treatment of tacrolimus and everolimus increases oxidative stress by pharmacological interactions. 2014 Transplantation pmid:24825522
Jain AB et al. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report. 1998 Transplantation pmid:9846530
Herzog D et al. Normal glomerular filtration rate in long-term follow-up of children after orthotopic liver transplantation. 2006 Transplantation pmid:16534467
Josephson MA et al. Treatment of renal allograft polyoma BK virus infection with leflunomide. 2006 Transplantation pmid:16534472
Ochiai T et al. Optimal serum trough levels of FK506 in renal allotransplantation of the beagle dog. 1989 Transplantation pmid:2474208
Ochiai T et al. Effects of combination treatment with FK506 and cyclosporine on survival time and vascular changes in renal-allograft-recipient dogs. 1989 Transplantation pmid:2474209
Hariharan S Case 2: strategies to minimize the use of calcineurin inhibitors (CNIs). 2002 Transplantation pmid:12357988
Schena FP et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. 2009 Transplantation pmid:19155978
Gouraud A et al. Follow-up of tacrolimus breastfed babies. 2012 Transplantation pmid:22996303
Muraki T et al. Antithrombotic effect of FK506 versus prothrombotic effect of cyclosporine in vivo. 1995 Transplantation pmid:7544038
Fridell JA et al. Causes of mortality beyond 1 year after primary pediatric liver transplant under tacrolimus. 2002 Transplantation pmid:12499888
Aw MM et al. Basiliximab (Simulect) for the treatment of steroid-resistant rejection in pediatric liver transpland recipients: a preliminary experience. 2003 Transplantation pmid:12660504
Kim SJ et al. A comparison of the effects of C2-cyclosporine and C0-tacrolimus on renal function and cardiovascular risk factors in kidney transplant recipients. 2006 Transplantation pmid:17038908
Saad ER et al. Successful treatment of BK viremia using reduction in immunosuppression without antiviral therapy. 2008 Transplantation pmid:18360267
Uchikoshi F et al. Restoration of immune abnormalities in diabetic BB rats after pancreas transplantation. I. Macrochimerism of donor-graft-derived RT6+ T cells responsible for restoration of immune responsiveness and suppression of autoimmune reaction. 1996 Transplantation pmid:8669109
Bolley R et al. Tacrolimus-induced nephrotoxicity unmasked by induction of the CYP3A4 system with St John's wort. 2002 Transplantation pmid:11923712
Mendez R et al. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year. 2005 Transplantation pmid:16082323
Oku M et al. Hepatocyte growth factor sustains T regulatory cells and prolongs the survival of kidney allografts in major histocompatibility complex-inbred CLAWN-miniature swine. 2012 Transplantation pmid:22158517